Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Jain, Michael D. , Spiegel, Jay Y. , Nastoupil, Loretta J. , Tamaresis, John , Ghobadi, Armin , Lin, Yi , Lekakis, Lazaros J. , Oluwole, Olalekan O. , McGuirk, Joseph P. , Deol, Abhinav , Dorritie, Kathleen , Sehgal, Alison R. , Hill, Brian T. , Ulrickson, Matthew L. , Patel, Dilan A. , Jacobs, Miriam T. , Bansal, Radhika , Patel, Vivek , Rapoport, Aaron P. , Neelapu, Sattva S. , Lunning, Matthew A. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Munoz, Javier L , Ulrickson, Matthew , Westin, Jason R , Chavez, Julio C , Patel, Dilan , Jacobs, Miriam T , Bansal, Radhika , Bennani, N Nora , Rapoport, Aaron P , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Locke, Frederick L , Dahiya, Saurabh , Jain, Michael D , Lin, Yi , Nastoupil, Loretta J , Ghobadi, Armin , Reagan, Patrick Michael , Andreadis, Charalambos Babis , Muñoz, Javier , Westin, Jason R. , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L.

Journal of Clinical Oncology | August 2, 2024 | Volume: 42 | Issue: 30 | Pages: 3581-3592

10.1200/jco.23.02786 | PMID 39094076 Get It

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse ( P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.
Revision total elbow arthroplasty is associated with a high rate of 30-day complications: A descriptive analysis of a national database
El-Najjar, Dany , Gupta, Puneet , Peterson, Joel R. , Rogalski, Brandon L. , Levine, William N. , Gupta, Puneet , Marigi, Erick M. , El-Najjar, Dany B , Mehta, Apoorva , Trofa, David P , Jobin, Charles M.

Shoulder & Elbow | August 2, 2024 | Volume: 17 | Issue: 5 | Pages: 634-640

10.1177/17585732241269001 | PMID 39552697 Get It

Introduction Revision total elbow arthroplasty (TEA) is indicated for component loosening, periprosthetic joint infection, and fractures. Previous investigations into revision TEA complications have small sample sizes and limited exploration of acute complications. This study aims to characterize the 30-day complications and associated demographics of patients undergoing revision TEA using a large national database. Methods The 2015–2020 American College of Surgeons National Surgical Quality Improvement Program database was used to identify all revision TEA patients. Results The analysis included 158 patients (average age 62.6 years). The overall complication rate was 13.9% ( n = 22). The most common 30-day complications were organ/space surgical site infection (3.8%, n = 6), unplanned readmission (3.2%, n = 5), intraoperative or postoperative transfusion (3.2%, n = 5), and unplanned reoperation (1.9%, n = 3). Patients with a history of dyspnea or steroid/immunosuppressant use for a chronic condition had significantly higher rates of bleeding requiring transfusion ( p = .029 and p = .021, respectively). Additionally, patients aged 80 years or older had a significantly higher rate of unplanned readmission ( p = .032). Conclusion Revision TEA has a 13.9% rate of complications within 30-days of surgery, with most involving surgical site infection, unplanned readmission, and blood transfusion. Level of Evidence IV.
Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Smith, Eric , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Marasco, Giovanni , Crinò, Stefano Francesco , Khashab, Mouen A., Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Wang, Yichen , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Facciorusso, Antonio , Khashab, Mouen A.

Endoscopy | August 2, 2024 | Volume: 57 | Issue: 03 | Pages: 272-281

10.1055/a-2378-9533 | PMID 39094769 Get It

AbstractEndoluminal radiofrequency ablation (RFA) is a palliative treatment for patients suffering from malignant biliary obstruction (MBO). We aimed to conduct a meta-analysis to evaluate the impact of RFA on stent patency, patient survival, and adverse events.Major databases were searched through December 2023 for patients who had undergone stenting with or without RFA for extrahepatic MBO. A random-effects model was used for analysis, with results expressed as relative risk ratios (RRs) with 95%CIs.Nine RCTs involving 750 subjects with MBO (374 RFA plus stent vs. 376 stent only) were included. Meta-analysis revealed similar risks of stent patency at 3 months (RR 1.01, 95%CI 0.92–1.11; I 2 = 4%) for RFA plus stenting vs. stent only. Meta-analysis showed improved survival at 6 months (RR 0.84, 95%CI 0.73–0.96; I 2 = 21%; P = 0.01) for RFA plus stenting vs. stent only. Subgroup analysis comparing plastic vs. uncovered metal stents showed that stent patency was unaffected at 3 months (RR 1.06, 95%CI 0.91–1.23; I 2 = 17%). Subgroup analysis showed that patients with cholangiocarcinoma experienced an overall survival benefit with RFA plus stenting vs. stenting alone (P < 0.001); however, stent patency remained unaffected (P = 0.08). An increased incidence of cholecystitis was noted with RFA plus stenting vs. stenting alone (5.1% [95%CI 3.1%–7.8%] vs. 0.3% [95%CI 0.01%–1.5%], respectively).Combining endoluminal RFA and stenting may improve overall survival in patients with MBO. RFA did not significantly impact stent patency.
Nurse Practitioner and Physician Assistant-led Cardiovascular Surgery Postoperative Intensive Care Unit Staffing Model
Perry, Ralph T., Weimer, John, Pratt, Carrie, Newcome, Marci, Bagameri, Gabor, Weimer, John W. , Newcome, Marci D., Bohman, John K , Bohman, J. Kyle

Journal of Intensive Care Medicine | August 2, 2024 | Volume: 40 | Issue: 2 | Pages: 178-183

10.1177/08850666241268458 | PMID 39094588 Get It

Objectives To determine whether a nurse practitioner and physician assistant (NP/PA)-led rapid staffing. Model in the cardiac surgical intensive care unit (ICU) can optimize resource utilization without compromising safety or increasing hospital length of stay (LoS). Design Retrospective observational cohort study comparing before-and-after implementation of an NP/PA-led rapid recovery pathway. Setting A large tertiary referral academic cardiac surgery ICU. Participants There were 116 patients in the prerapid recovery cohort and 153 in the postimplementation rapid recovery phase. Interventions Low-risk cardiac surgery patients were selected for postoperative care by an NP/PA-led ICU staffing model. Measurements and Main Results Mean hospital LoS in the prerapid recovery cohort was 5.7 days compared to 5.2 days in the rapid recovery pathway cohort ( P = .02). Thirty-day hospital readmission in the prerapid recovery pathway cohort was 7.8% compared with 2.0% in the rapid recovery cohort ( P = .04). The ICU readmission rate for prerapid recovery cohort was 4.3%, while the rapid recovery percentage was 2.0% ( P = .30). Conclusions Overall, implementation of an NP/PA-led postcardiac surgical ICU team ( rapid recovery pathway) was associated with similar ICU LoS, hospital LoS, ICU readmission rates, 30-day readmission rates, and no significant signal of increased adverse events or safety concerns.
Pulsed Vibro-Acoustic Analysis Technique for Monitoring Bone Health in Preterm Infants: A Pilot Study
Chaudhary, Pradeep Kumar , Rosen, David , Larson, Nicholas B. , Brumbaugh, Jane E. , Fatemi, Mostafa , Gu, Juanjuan, Rosen, David P , Fatemi, Mostafa , Larson, Nicholas B , Brumbaugh, Jane E , Gu, Juanjuan , Alizad, Azra

IEEE Access | August 2, 2024 | Volume: 12 | Issue: No issue available | Pages: 106707-106719

10.1109/access.2024.3437375 | PMID 39148928 Get It

Postvasectomy Semen Analysis Compliance With Utilization of a Mail-In Semen Analysis Kit
Gu, Catherine , Belarmino, André , Nolte, Daniel, Civello, Daniel, Honig, Stanton, Kenfield, Stacey A. , Smith, Daron , Mehta, Akanksha , Punjani, Nahid , Lerner, Lori B.

Journal of Urology | August 2, 2024 | Volume: 212 | Issue: 6 | Pages: 899-906

10.1097/ju.0000000000004185 | PMID 39093876 Get It

Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Lai, Chuanxi , Lv, Yiming , Zhang, Feixiang , Shi, Liming , Wang, Yunfei , Shen, Yanbin , Xu, Lingna , Hu, Peng , Tang, Wen, Xu, Dengyong, Cao, Gaoyang , Shan, Lina , Jia, Xiya, Chen, Yiyi , Wang, Da , Lao, Weifeng , Sun, Xiaonan , Wang, Fei , Hu, Peng, Larson, David W. , Gu, Hongcang , Huang, Xuefeng , Dai, Sheng

International Journal of Surgery | August 2, 2024 | Volume: 111 | Issue: 1 | Pages: 334-345

10.1097/js9.0000000000001960 | PMID 39093871 Get It

Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P &lt; .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria
Breeggemann, Matthew C. , Wood, Kyle D. , Harris, Peter C. , Lieske, John C. , Tasian, Gregory E.

Journal of Urology | August 2, 2024 | Volume: 212 | Issue: 5 | Pages: 649-659

10.1097/ju.0000000000004147 | PMID 39093847 Get It